You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Litigation Details for ALKERMES, INC. v. TEVA PHARMACEUTICAL INDUSTRIES USA,INC (D.N.J. 2020)


✉ Email this page to a colleague

« Back to Dashboard


ALKERMES, INC. v. TEVA PHARMACEUTICAL INDUSTRIES USA,INC (D.N.J. 2020)

Docket ⤷  Try a Trial Date Filed 2020-09-09
Court District Court, D. New Jersey Date Terminated 2023-08-30
Cause 28:1338 Patent Infringement Assigned To Madeline Cox Arleo
Jury Demand None Referred To Michael A. Hammer
Parties ALKERMES PHARMA IRELAND LIMITED; TEVA PHARMACEUTICALS USA, INC.
Patents 6,264,987; 6,495,155; 7,919,499; 8,008,006
Attorneys CHARLES MICHAEL LIZZA; SARAH ANN SULLIVAN
Firms Kean University
Link to Docket External link to docket
Small Molecule Drugs cited in ALKERMES, INC. v. TEVA PHARMACEUTICAL INDUSTRIES USA,INC
The small molecule drugs covered by the patents cited in this case are ⤷  Try a Trial and ⤷  Try a Trial .
Biologic Drugs cited in ALKERMES, INC. v. TEVA PHARMACEUTICAL INDUSTRIES USA,INC
The biologic drugs covered by the patents cited in this case are ⤷  Try a Trial and ⤷  Try a Trial .

Details for ALKERMES, INC. v. TEVA PHARMACEUTICAL INDUSTRIES USA,INC (D.N.J. 2020)

Date Filed Document No. Description Snippet Link To Document
2020-09-09 1 Complaint -Controlled Clinical Trial, "Alco- 6,264,987 B1 7/2001 Wright et al. … 3 process described in U.S. Pat. No. 6,264,987, by Wright et al., weight, more preferably… release include pore example, U.S. Pat. No. 6,264,987 to Wright, U.S. Pat. Nos. forming…expiration date of the ’499 patent, including any patent term extensions and/or patent term adjustments, and… of 28 PageID: 10 patent, including any patent term extensions and/or patent term adjustments, and External link to document
2023-02-18 207 Brief partes review Patent-in-Suit or U.S. Patent No. 7,919,499 to E. Ehrich,… Patent Trial and Appeal Board at the PTO PTO U.S. Patent and Trademark… the patent claims, specification, and prosecution history underlying the grant of the patent is plain… Post-Grant Review Decisions by the Patent Office ........................................…Ehrich, PTX-1 ’499 Patent POSA Person of ordinary skill in the art PTAB External link to document
2023-04-12 224 Trial Brief Wright et al., U.S. Patent No. 6,264,987, titled “Method for Wright …-1) ’499 Patent Patent Prosecution History of U.S. Patent No. 7,919,499… The ’499 Patent A. Overview of the ’499 Patent The ’499 Patent explains that… Patent-in-Suit U.S. Patent No. 7,919,499, titled “…17, 2005 (PTX-52) (PTX-179) Patent-in-suit The ’499 Patent External link to document
2023-05-19 229 Trial Brief ’499 Patent Prosecution Patent Prosecution History of U.S. Patent No. 7,919,499 (DTX-002)… Patent-in-Suit U.S. Patent No. 7,919,499, titled “Naltrexone …March 17, 2005 (PTX-52) (PTX-179) Patent-in-suit The ’499 Patent …pharmacokinetics (for whom the patent is written) has not just the patent claims …many, many patent cases (but not this one) involve genuine issues of infringement, and patents 4 External link to document
2023-08-02 253 Redacted Document TABLE OF ABBREVIATIONS ’499 Patent U.S. Patent No. 7,919,499 Alkermes Collectively… Alkermes obtained U.S. Patent No. 7,919,499 (the ’499 patent) to protect its monopoly on Vivitrol… herewith) Patent Office United States Patent and Trademark Office PLA …single day? Multiple days? The patent does not say. Remarkably, the patent specification contains no …rights A patent is a property right granted by the government to the patent owner. The claims External link to document
2023-08-02 254 Redacted Document TABLE OF ABBREVIATIONS ’499 patent U.S. Patent No. 7,919,499 Alkermes Collectively… Inter Partes Review Patent Office United States Patent and Trademark Office PLA …trial showed that Alkermes’s remaining patent—the asserted ’499 patent—is invalid. First, Alkermes…to save its patent from indefiniteness rely on blithely ignoring the text of the patent claims. The…reported in the patent at all, and he did not explain this “different path” to the Patent Office during External link to document
2023-08-30 258 Letter the event that the claims of U.S. Patent No. 7,919,499 (the “’499 Patent”) asserted against Teva are not…7975 authorization from Plaintiffs, the ‘499 Patent would be infringed by any unlicensed manufacture…, will be enjoined until expiration of the ‘499 Patent from (i) making, using, offering to sell, selling…infringement, validity, and/or enforceability of the ’499 Patent in any future litigation pertaining to any product…maintain its Paragraph IV certification to the ’499 Patent pursuant to 21 C.F.R. § 314.94(a)(12)(v) and this External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.